

Press release

Lund 18 September 2022

Scandinavian ChemoTech's IQwave™ used as first-line treatment with great clinical outcome in Ukraine

The oncology Ulis Hospital in Ukraine has reported great success where locally advanced squamous cell skin cancer has been treated with IQwave and Tumour Specific Electroporation™ (TSE), with a 90% remission with the expectation of full recovery.

As a result of the ongoing war in Ukraine, the patient was not able to get diagnosed and treated before the tumour grew to such a size that radiation therapy was deemed little chance of regression. Due to the placement and size of the tumour, surgery would have created major damage and the need for following plastic surgery and skin transplant would be inevitable. The patient declined surgery and TSE therapy was chosen to be a suitable option.

Not only has the TSE treatment given a 90% remission so far, but the team at Ulis also found biomarkers that prove that TSE generates a great Immunological response. A drastic increase in both CD45 and CD8, which are T-cell lipocytes, was observed through laboratory tests after the treatment and indicates that the immune system attacks the tumour.

"As a scientist, and at the same time as a practical oncologist with more than 25 years of experience, I am very pleased with the fact that such a treatment method as the TSE therapy has become available in the practice of Ukrainian doctors. We are very motivated to continue to use TSE to treat cancer patients but we see also great potential for more clinical research to use TSE as an immune therapy or to improve the efficacy of different immunotherapy molecules." – says Konstantin Kovalev, Candidate of Medical Sciences, Founder and director of the charity World Against Cancer Foundation

"After more than 4 years of frequent use of TSE around the world, and being a scientist, it's great news for us to finally get a complete documented case that clearly indicates the biomarkers that generate the incredible quick responses and healing off the tissue that we have seen in the past." - says Dr Suhail, Medical adviser at Scandinavian ChemoTech

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,

E-mail: certifiedadviser@penser.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-09-2022 18:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.